Department of Pharmacy and Pharmaceutical Sciences Residency Programs

Frequently Asked Questions

 
 

  1. Yes, all applicants are required to use the PhORCAS system to apply for their desired program.

  2. Yes, resident applicants are required to have completed a PGY1 residency prior to enrollment in any PGY2 experience as per ASHP-accreditation standards.

  3. Please contact the Tennessee Board of Pharmacy, or access its website for additional information and requirements for the State of Tennessee. Information about reciprocating licenses can be found at the National Boards of Pharmacy website.

  4. Residents in the Oncology Pharmacy, Clinical Pharmacogenomics and Infectious Diseases Pharmacy programs will be expected to cover two holidays. The specific holidays will be determined by the end of July.

  5. Residents are provided their own office spaces, and general office supplies are also readily available for the residents’ uses. Each resident is assigned a personal laptop computer to be used for the full academic year. Several reference texts will also be provided. The resident is given a professional development fund to be used for memberships, professional travel or additional residency/training-related items of his/her choice.

  6. Oncology residents

    Residents will be introduced to the department during July.  During the residency year, residents will be trained in operational processes within the department, including sterile products and chemotherapy preparation. Clinical coverage of weekends will be approximately every fourth weekend.

    Clinical Pharmacogenomics residents

    Residents will be introduced to the department during July.  Clinical coverage of weekends will be approximately every fourth weekend.

    Infectious Diseases Pharmacy residents

    Residents may be expected to provide up to 16 hours per month of weekend staffing coverage for ID/Antimicrobial Stewardship services.

    Medication-Use Safety and Policy residents

    Residents will be expected to provide up to 16 hours per month of pharmacy staffing coverage. Coverage will be approximately 4 hours per week in the early evening.

  7. The St. Jude Department of Pharmacy and Pharmaceutical Sciences accepts pharmacy students from across the country but primarily from the University of Tennessee College of Pharmacy. Residents are expected to assist in precepting students should their rotations overlap. Residents are also expected to lead group discussions and facilitate learning experiences for PharmD students.

  8. Residents are required to attend the ASHP Midyear Clinical Meeting in December. In addition, residents are required to present their research at a regional pharmacy conference.  Residents may have the opportunity to present at a national meeting, such as ACCP, ASCPT, ASHP, HOPA, PPA, or the PRGN conference. Additional meetings and an optional residency class trip may be available. 

  9. A background in biological sciences and basic human genetics is recommended but not required. The resident, through the help of key preceptors, will be expected to become proficient in all relevant topics in genetics that will be necessary to practice in the field of clinical pharmacogenomics.

  10. Examples of recent publications from St. Jude Department of Pharmacy and Pharmaceutical Sciences Residents

    Wu D, Williams MR, Patwardhan AA, Bi Y, Sekular S, Pauley JL, McCormick J, Sharma A. Concomitant azole initiation decreases time to stable goal sirolimus concentrations in pediatric allogeneic transplant recipients. J Pediatr Hematol Oncol. 2025. PMID: 40793923

    Phillips KJ, Sun Y, Tang L, Pappas A, Cross SJ, Pauley JL, McCormick J, Molinelli AR, Bissler JJ, Christensen AM, Stewart CF. Comparison of GFR estimation equations using creatinine, cystatin C, and their combination in pediatric hematology-oncology: no single equation is superior across subgroups. Pediatr Nephrol. 2025 Sep;40(9):2907-17. PMID: 40266335

    Matherne M, Panetta JC, Hopp J, Inaba H, Pui CH, Karol SE, Swanson HD. Desensitization to calaspargase pegol appears to be less successful than pegaspargase. Blood Adv. 2025 Apr 8;9(7):1492-1496.  PMID: 39903102

    Moody J, Barker PJ, Sciasci J, Pauley JL, Bragg A, McMillan C, Triplett BM, Swanson HD. Blinatumomab infusion interruptions in pediatric patients rarely lead to readmission. Pediatr Blood Cancer. 2024; 71 (10):e31223 PMID: 39054702

    King MA, Cross, SJ, Morton TH, Hijano DR, Greene WL, Sun Y, Tang L, Pauley JL, Bourque MS, Christensen AM. Evaluation of Continuous Infusion Vancomycin in a Pediatric Hematology/Oncology Population. Pediatr Infect Dis J. 2024;43(6):520-524. PMID: 38359358

    Gaietto A, Panetta JC, Pauley JL, Relling MV, Ribeiro R, Ehrhardt MJ, Pui CH, Inaba H, Swanson HD. Ommaya reservoir use in pediatric ALL and NHL: a review at St. Jude Children’s Research Hospital. Cancer Chemother Pharmacol. 2024; 93 (6): 617-625. PMID: 38416167

    Hughes K, Cole M, Tims D, Wallach T, Spencer C, Page V, Robertson J, Hoffman, JM.  Optimizing the use of dose error reduction software on intravenous infusion pumps. Hosp Pediatr. 2024. https://doi.org/10.1542/hpeds.2023-007385

    Sauer HE, Crews KR, Pauley JL, et al. Evaluation of aminophylline for the treatment of acute kidney injury in pediatric hematolog/oncology patients, J Pediatr Pharmacol. 2021;26(5):484-90.

    Lambrix AA, Swanson HD, Pauley JL, Bragg AW, Carias DC, Bourque MS, Zhou Y, Cheng C, Greene WL, Maron G. Experience using intravenous posaconazole in pediatric and young adult oncology patients. J Antimicrob Chemother. 75(12):3682-3687, 2020. PMID: 32929484

    Daniels CC, Burlison JD, Baker DK, Robertson J, Sablauer A, Flynn PM, Campbell PK, Hoffman JM. Optimizing drug-drug interaction alerts using a multidimensional approach. Pediatrics. Mar 2019; 143(3): e20174111.

    Quinn M, Fannin JT, Sciasci J, Bragg A, Campbell PK, Carias D, Crews KR, Gregornik D, Jeha S, Maron G, Pauley JL, Swanson HD, Wolf J, Greene WL.  Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy.  Antimicrob Agents Chemother. Jul 27;62(8), 2018. PMID: 29866879

    Burlison JD, McDaniel RB, Baker DK, Hasan M, Robertson JJ, Howard SC, Hoffman JM. Using EHR data to detect prescribing errors in rapidly discontinued medication orders. Appl Clin Inform. Jan;9(1):82-8, 2018. PMID 29388181

    Pasternak AL, Crews KR, Caudle KE, Smith C, Pei D, Cheng C, Broeckel U, Gaur A, Relling MV, Haidar CE. An analysis of the impact of the UGT1A1 *60 allele on bilirubin serum concentrations. Pharmacogenomics Jan;18(1):5-16, 2017. PMID: 27967321

    Millisor VE, Roberts JK, Sun Y, Tang L, Daryani VM, Gregornik D, Cross SJ, Ward D, Pauley JL, Molinelli A, Brennan RC, Stewart CF. Derivation of new equations to estimate glomerular filtration rate in pediatric oncology patients. Pediatr Nehprol Sep;32(9):1575-84, 2017. PMID: 28573537

    Watts CS, Sciasci JN, Pauley JL, Panetta JC, Pei D, Cheng C, Christensen CM, Mikkelsen TS, Pui CH, Jeha S, Relling MV. Prophylactic trimethoprim-sulfamethoxazole does not affect pharmacokinetics or pharmacodynamics of methotrexate. J Pediatr Hemaol Oncol Aug; 38(6):449-52, 2016. PMID: 28715509

    Gammal RS, Crews KR, Haidar CE, Hoffman JM, Baker DK, Barker PJ, Estepp JH, Pei D, Broeckel U, Wang W, Weiss MJ, Relling MV, Hankins JS. Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease. Pediatrics Jul;138(1), 2016. PMID: 27335380

    McDaniel RB, Burlison JD, Baker DK, Hasan M, Robertson J, Hartford C, Howard SC, Sablauer A, Hoffman JM. Alert dwell time: introduction of a measure to evaluate interruptive clinical decision support alerts. J Am Med Inform Assoc Apr;23(e1):e138-41, 2016. PMID: 26499101

    Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, Guillemette C, Lennox JL, Whirl-Carrillo M, Brummel S, Ratain MJ, Klein TE, Schackman BR, Caudle KE, Haas DW. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther Apr;99(4):363-9, 2016. PMID: 26417955

    Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC, Hunkler RJ, Klein TE, Evans WE, Relling MV. Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five United States Medical Centers. Annu Rev Pharmacol Toxicol 55:89-106, 2015. PMID: 25292429

 
 

Close
Close